novo nordisk glp 1 drug launches Wegovy weight-loss pill in US, triggering price war | Pharmaceuticals industry Ozempic for everyone? Inside Novo
Description
As GLP-1 agonists have garnered attention for management of obesity due to their effect on reducing insulin sensitivity, they are now being considered a therapeutic option for the treatment of PCOS (polycystic ovarian syndrome), one of the most common causes of subfertility, diagnosed via Rotterdams criteria: oligomenorrhea, hyperandrogenism and polycystic ovaries (97)
Furthermore, recent data indicates effectiveness in inhibiting fibrosis advancement, with clinical studies revealing markedly reduced progression rates in individuals treated with semaglutide (5%) compared to placebo groups (19%) (Newsome et al
5i) in either the Glp1r fl/fl or Glp1r Wnt1/ mice
Griffith DA, Edmonds DJ, Fortin JP, Kalgutkar AS, Kuzmiski JB, Loria PM, et al
[DOI] [PMC free article] [PubMed] [Google Scholar] 924.Evers A., Haack T., Lorenz M., Bossart M., Elvert R., Henkel B
A 2024 study suggests injectable semaglutide leads to more weight loss in real-world settings
